PCSK9 Inhibitors May Benefit Patients with Acute Coronary Syndrome

Results of a recent study published in the Annals of Internal Medicineshowed that patients with acute coronary syndrome (ACS) who were treated with PCSK9 inhibitors benefited not only from LDL-cholesterol reduction but plaque stabilization as well. Currently, the PCSK9 inhibitors evolocumab and alirocumab are approved for lowering of LDL in patients with familial hypercholesterolemia or […]

As PCSK9 Inhibitors Come to Market, Concern Over 2013 Guidelines Resurfaces

Now that the first PCSK9 inhibitors have received FDA approval, the ambiguity of the 2013 ACC/AHA cholesterol-treatment guidelines are again being called into question. Because the new class of LDL-lowering agents are expensive specialty medications, with alirocumab priced at about $14,600 per year, payers are expressing concern that the removal of specific LDL-C targets from the […]